Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins

Hepatitis C virus (HCV) and triglyceride-rich very low-density lipoproteins (VLDLs) both are secreted uniquely by hepatocytes and circulate in blood in a complex. Here, we isolated from human hepatoma cells the membrane vesicles in which HCV replicates. These vesicles, which contain the HCV replication complex, are highly enriched in proteins required for VLDL assembly, including apolipoprotein B (apoB), apoE, and microsomal triglyceride transfer protein. In hepatoma cells that constitutively produce infectious HCV, HCV production is reduced by two agents that block VLDL assembly: an inhibitor of microsomal triglyceride transfer protein and siRNA directed against apoB. These results provide a possible explanation for the restriction of HCV production to the liver and suggest new cellular targets for treatment of HCV infection... Whole article: "PNAS"[ http://www.pnas.org/cgi/content/full/104/14/5848]

---

Related articles

Researcher Announced Cure for Hepatitis C - The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis, liver cancer and the need for liver transplant, a Virginia Commonwealth University researcher said today (25.5.2007)

Scientists Develop Artificial Blood - Scientists from the University of Sheffield are developing an artificial 'plastic blood´, which could act as a substitute for real blood in emergency situations (16.5.2007)

Hepatitis C Growth In Liver Cells Slowed By Protein - Biomedical researchers have identified a cellular protein that interferes with hepatitis C virus replication, a finding that ultimately may help scientists develop new drugs to fight the virus (4.5.2007)

ViroPharma Announces Presentation Of New HCV-796 In Vitro Data At The 13th International Meeting On Hepatitis C Virus & Related Viruses - ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of additional preclinical data on HCV-796, an orally dosed non-nucleoside hepatitis C virus (HCV) polymerase inhibitor being co-developed with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), at the 13th International Meeting on Hepatitis C Virus & Related Viruses in Cairns, Australia (5.9.2006)

Genetic Test to Give Clues on Treatment of Hepatitis C - Celera Genomics plans to announce today that it has developed a genetic test it says can help predict which patients with hepatitis C will eventually suffer liver scarring and so are in most need of treatment (9.5.2006)